China’s New Essential Drug List Adds Drugs For Major Diseases, But Pricing, Market Pressure Likely To Increase
This article was originally published in The Pink Sheet Daily
China adds 14 new oncology drugs to its newly revised Essential Drug List, as well as human insulins and hemophilia agents for the first time. Notable MNC drugs include Pfizer’s Norvasc, Novartis’ Diovan, Sanofi’s blood thinner Plavix and Bayer’s Glucobay.
You may also be interested in...
Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.